Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin-L2 is a member of the cyclin family whose protein product interacts with multiple factors, including RNA polymerase II, splicing proteins, and cyclin-dependent kinases. It functions in regulating pre-mRNA splicing and may induce apoptosis by modulating the transcription and RNA processing of apoptosis-related genes. The gene has multiple alternatively spliced transcript variants leading to different isoforms. CCNL2 is associated with some cancers, such as retinal and ocular cancer, but is not recognized as a direct therapeutic drug target or receptor[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin-L2 (CCNL2).